BofA raised the firm’s price target on Krystal Biotech (KRYS) to $255 from $182 and keeps a Buy rating on the shares. The firm, which continues to like Vyjuvek, Krystal’s drug treating the rare skin condition dystrophic epidermolysis bullosa, also adjusts its pipeline and platform contribution estimates to add standalone revenue builds for KB801 and KB803 as it believes near-term pipeline data could be “value unlocking.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Krystal Biotech gets FDA platform technology designation to HSV-1 viral vector
- Krystal Biotech’s Growth Potential Bolstered by FDA Approval and Promising Pipeline Developments
- Buy Rating for Krystal Biotech Driven by Vyjuvek’s Expanded Label and Market Potential
- Krystal Biotech announces FDA approval of update VYJUVEK label
- 3 ‘Outperform’ Healthcare Stocks, According to AI Analyst, 9/10/25